A. Hollebecque, E. Dotan, C.Y.A. Liao, D. Roda, E. Fontana, H. Babiker, R.D. Kim, D.Y. Oh, F. Ghiringhelli, I. Moreno, J. Liu, V. Subbiah, A. Varkaris, M.J. Borad, P.A. Cassier, A. Deary, F.T. Ramirez, F. Ricard, K.Y. Jen, A.M. Schram
{"title":"58 (PB046):高选择性表皮生长因子受体2(FGFR2)融合或重排(f/r)晚期实体瘤患者(pts)中利拉伐替尼(lirafugratinib)的肿瘤诊断疗效和安全性:ReFocus研究","authors":"A. Hollebecque, E. Dotan, C.Y.A. Liao, D. Roda, E. Fontana, H. Babiker, R.D. Kim, D.Y. Oh, F. Ghiringhelli, I. Moreno, J. Liu, V. Subbiah, A. Varkaris, M.J. Borad, P.A. Cassier, A. Deary, F.T. Ramirez, F. Ricard, K.Y. Jen, A.M. Schram","doi":"10.1016/j.ejca.2024.114585","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":7.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study\",\"authors\":\"A. Hollebecque, E. Dotan, C.Y.A. Liao, D. Roda, E. Fontana, H. Babiker, R.D. Kim, D.Y. Oh, F. Ghiringhelli, I. Moreno, J. Liu, V. Subbiah, A. Varkaris, M.J. Borad, P.A. Cassier, A. Deary, F.T. Ramirez, F. Ricard, K.Y. Jen, A.M. Schram\",\"doi\":\"10.1016/j.ejca.2024.114585\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804924012760\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924012760","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.